Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：1
|
作者：
Schuler, M. [1 ]
Yang, J. [2 ,3 ]
Sequist, L. V. [4 ,5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
O'Byrne, K. [8 ,9 ]
Hirsh, V. [10 ]
Mok, T. [11 ]
Shah, R. [12 ]
Wu, Y. -L. [13 ,14 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ, Taipei, Taiwan
[4] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China
[8] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[9] Queensland Univ Technol, Brisbane, Qld, Australia
[10] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[11] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China
[12] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[13] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[14] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30248-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138PD
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [31] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Park, K.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
    Paz-Ares, L.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T. S. K.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] First-line afatinib in patients with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trials
    Schuler, M.
    Paz-Ares, L.
    Sequist, L. V.
    Sebastian, M.
    Wu, Y. -L.
    Geater, S. L.
    Maerten, A.
    Fan, J.
    Park, K.
    Yang, J. C. -H.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 172 - 172
  • [34] First-line afatinib for advanced EGFRm1 NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
    Schuler, M.
    Paz-Ares, L.
    Sequist, L. V.
    Wu, Y-L.
    Geater, S. L.
    Maerten, A.
    Fan, J.
    Park, K.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L.
    Tan, E. -H.
    O'Byrne, K.
    Zhang, L.
    Hirsh, V.
    Boyer, M.
    Yang, J. C. -H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Lee, D. H.
    Laskin, J.
    Kim, D. -W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Marten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 270 - 277
  • [36] ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
    Yang, J. C.
    Schuler, M.
    Yamamoto, N.
    O'Byrne, K. J.
    Hirsh, V.
    Mok, T. S. K.
    Massey, D.
    Zazulina, V.
    Shahidi, M.
    Sequist, L. V.
    ANNALS OF ONCOLOGY, 2012, 23 : 410 - 411
  • [37] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Symptom and Quality of Life Improvement in LUX-Lung 6 An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer
    Geater, Sarayut L.
    Xu, Chong-Rui
    Zhou, Caicun
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Shi, Jian Hua
    Lee, Kye Young
    Palmer, Michael
    Shi, Yang
    Lungershausen, Juliane
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 883 - 889
  • [39] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
    Hirsh, Vera
    Park, Keunchil
    Tan, Eng-Huat
    Zhang, Li
    O'Byrne, Kenneth
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Fan, Jean
    Massey, Dan
    Paz-Ares, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [40] Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
    Park, K.
    Tan, E-H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Kim, M.
    Massey, D.
    Zazulina, V.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 161 - 162
12345